QualityStocksNewsBreaks – Numinus Wellness Inc. (TSX.V: NUMI), Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) Partner in Pre-Clinical Trial Application for Psilocybin Extract
Numinus Wellness (TSX.V: NUMI), a mental-health-care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, has joined with Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) to submit an all-natural psilocybin extract to Health Canada for pre-clinical trial approval. Optimi Health is the developer of a vertically integrated functional mushroom brand focused on the health and wellness sector. The submission to Health Canada marks a significant milestone in the development of the extract. The two companies submitted the application through Impact Clinical Trials Accelerator at the University of Calgary; validation studies as well as cultivation, research, and formulation have been conducted…